Pomerantz LLP is investigating claims against Scholastic Corporation and its executives for possible securities fraud following the company's Q1 fiscal 2027 report. Scholastic reported an adjusted loss of $3.63 per share, missing estimates, and a 4% revenue decline to $216.8 million, with a 24% drop in its Education segment due to tighter school budgets. The stock fell 7.41% after the announcement. The investigation could lead to a class action lawsuit if misconduct is found.
Scholastic Corporation news provides context for readers. For those tracking Consumer Cyclical stocks, 72 of 134 rose and 62 fell on Pluang. Notable movers include Rush Street Interactive Inc at USD 15.33 with a 5.95% drop, Bath & Body Works Inc at USD 21.61 up 5.80%, and Stitch Fix Inc at USD 2.72 with 100% buy orders. Data is as of Oct 28, 2026 04:32 WIB.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
